{"id":"https://openalex.org/W4394601902","doi":"https://doi.org/10.1212/wnl.0000000000206336","title":"Long-term Effectiveness of Cannabidiol (CBD) Against Focal-onset Seizures in Treatment-resistant Epilepsies (TRE): Experience from the Expanded Access Program (EAP) (S29.005)","display_name":"Long-term Effectiveness of Cannabidiol (CBD) Against Focal-onset Seizures in Treatment-resistant Epilepsies (TRE): Experience from the Expanded Access Program (EAP) (S29.005)","publication_year":2024,"publication_date":"2024-04-09","ids":{"openalex":"https://openalex.org/W4394601902","doi":"https://doi.org/10.1212/wnl.0000000000206336"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.0000000000206336","doi":"https://doi.org/10.1212/wnl.0000000000206336","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.0000000000206336","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5023527480","display_name":"Yong Park","orcid":"https://orcid.org/0000-0001-7909-6639","observed_orcids":["https://orcid.org/0000-0001-7909-6639"]},"institutions":[{"id":"https://openalex.org/I25041050","display_name":"Augusta University","ror":"https://ror.org/012mef835","country_code":"US","type":"education","lineage":["https://openalex.org/I25041050"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yong Park","raw_affiliation_strings":["Medical College of Georgia at Augusta University, Department of Neurology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical College of Georgia at Augusta University, Department of Neurology","institution_ids":["https://openalex.org/I25041050"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085822933","display_name":"Karthik Rajasekaran","orcid":"https://orcid.org/0000-0003-2148-1643","observed_orcids":["https://orcid.org/0000-0003-2148-1643"]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karthik Rajasekaran","raw_affiliation_strings":["Jazz Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Teresa Greco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Teresa Greco","raw_affiliation_strings":["Jazz Pharmaceuticals, Inc, Gentium Srl"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Inc, Gentium Srl","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008258554","display_name":"Farhad Sahebkar","orcid":"https://orcid.org/0000-0002-7748-7836","observed_orcids":["https://orcid.org/0000-0002-7748-7836"]},"institutions":[{"id":"https://openalex.org/I4210101297","display_name":"Jazz Pharmaceuticals (United States)","ror":"https://ror.org/019rsbe67","country_code":"US","type":"company","lineage":["https://openalex.org/I4210101297","https://openalex.org/I4210152300"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Farhad Sahebkar-Moghaddam","raw_affiliation_strings":["Jazz Pharmaceuticals, Inc"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Jazz Pharmaceuticals, Inc","institution_ids":["https://openalex.org/I4210101297"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015287175","display_name":"Robert J. Flamini","orcid":"https://orcid.org/0000-0001-5095-3166","observed_orcids":["https://orcid.org/0000-0001-5095-3166"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Flamini","raw_affiliation_strings":["PANDA Neurology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"PANDA Neurology","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2436,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.45152603,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":91,"max":95},"biblio":{"volume":"102","issue":"7_supplement_1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.8833000063896179,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.8833000063896179,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10414","display_name":"Cannabis and Cannabinoid Research","score":0.10440000146627426,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12267","display_name":"Diet and metabolism studies","score":0.00139999995008111,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cannabidiol","display_name":"cannabidiol","score":0.9990000128746033},{"id":"https://openalex.org/keywords/epidiolex","display_name":"Epidiolex","score":0.7799999713897705},{"id":"https://openalex.org/keywords/drug-resistant-epilepsy","display_name":"drug-resistant epilepsy","score":0.8889999985694885},{"id":"https://openalex.org/keywords/focal-seizures","display_name":"focal seizures","score":0.9769999980926514},{"id":"https://openalex.org/keywords/focal-aware-seizures","display_name":"focal aware seizures","score":0.9369999766349792},{"id":"https://openalex.org/keywords/complex-partial-seizures","display_name":"complex partial seizures","score":0.9950000047683716},{"id":"https://openalex.org/keywords/focal-to-bilateral-tonic-clonic-seizures","display_name":"focal to bilateral tonic-clonic seizures","score":0.9929999709129333},{"id":"https://openalex.org/keywords/expanded-access-program","display_name":"expanded access program","score":0.7889999747276306},{"id":"https://openalex.org/keywords/seizure-frequency-reduction","display_name":"seizure frequency reduction","score":0.8209999799728394},{"id":"https://openalex.org/keywords/responder-rate","display_name":"responder rate","score":0.722000002861023},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5490000247955322},{"id":"https://openalex.org/keywords/long-term-safety","display_name":"long-term safety","score":0.4440000057220459},{"id":"https://openalex.org/keywords/pediatric-epilepsy","display_name":"pediatric epilepsy","score":0.5619999766349792},{"id":"https://openalex.org/keywords/antiepileptic-drug-withdrawal","display_name":"antiepileptic drug withdrawal","score":0.5630000233650208},{"id":"https://openalex.org/keywords/antiepileptic-drug-resistance","display_name":"antiepileptic drug resistance","score":0.48899999260902405}],"concepts":[{"id":"https://openalex.org/C2776895053","wikidata":"https://www.wikidata.org/wiki/Q422917","display_name":"Cannabidiol","level":3,"score":0.8147662878036499},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.6403859853744507},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.49912071228027344},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3502659797668457},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.21992838382720947},{"id":"https://openalex.org/C2777056318","wikidata":"https://www.wikidata.org/wiki/Q79817","display_name":"Cannabis","level":2,"score":0.05556368827819824}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.0000000000206336","doi":"https://doi.org/10.1212/wnl.0000000000206336","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.0000000000206336","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3201472615","https://openalex.org/W4394599685","https://openalex.org/W2818962606","https://openalex.org/W4412488533","https://openalex.org/W3135822044","https://openalex.org/W4378515016","https://openalex.org/W2885628427","https://openalex.org/W4312019071","https://openalex.org/W3091395003","https://openalex.org/W4308342875"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"report":[2],"the":[3,244,349,367,386],"effect":[4],"of":[5,69,80,130,132,179,304,318,332,351,369,388],"CBD":[6,36,51,139,147,172,272],"in":[7,43,76,243,278,339,348,366,385],"EAP":[8,32,99],"patients":[9,220],"with":[10,39,176,221,276,281],"focal-onset":[11],"seizures,":[12],"including":[13],"focal":[14,18,24,81,104,223,279],"aware":[15],"seizures":[16,21,28,82,280],"(FAS),":[17,181],"impaired":[19],"awareness":[20],"(FIAS),":[22,183],"and":[23,63,83,167,184,197,207,216,228,261,265],"to":[25,66,235,291],"bilateral":[26],"tonic-clonic":[27],"(FBTCS).":[29,186],"Background:":[30],"Four-year":[31],"results":[33],"demonstrated":[34],"that":[35],"was":[37,174,274],"associated":[38,175,275],"sustained":[40],"seizure":[41,157],"improvement":[42],"TRE.":[44],"Design/Methods:":[45],"Patients":[46,126],"received":[47,296,310,324,345,363,382],"plant-derived":[48],"highly":[49],"purified":[50],"(Epidiolex":[52],"\u00ae":[53],";":[54],"100":[55],"mg/mL":[56],"oral":[57],"solution)":[58],"starting":[59],"at":[60,115],"2\u201310":[61],"mg/kg/d":[62,150],"further":[64],"titrated":[65],"a":[67,356,374,393],"maximum":[68],"25\u201350":[70],"mg/kg/d.":[71],"Percentage":[72],"change":[73],"from":[74],"baseline":[75],"median":[77,154,177],"monthly":[78,156],"frequency":[79],"responder":[84],"rates":[85],"(RRs)":[86],"across":[87],"12-week":[88],"intervals":[89],"through":[90],"144":[91],"treatment":[92,173,273],"weeks":[93],"were":[94,190,204,213,258],"evaluated.":[95],"Results:":[96],"Of":[97],"892":[98],"patients,":[100],"351":[101],"(39%)":[102],"experienced":[103],"seizures.":[105],"Mean":[106],"(range)":[107,113],"age:":[108],"15.8":[109],"(<1\u201373.2)":[110],"years.":[111],"Median":[112,138,145],"ASMs":[114],"baseline:":[116],"3":[117],"(0\u201310).":[118],"Most":[119,246],"common":[120,247],"ASMs:":[121],"clobazam":[122],"(43%),":[123],"levetiracetam":[124],"(35%).":[125],"withdrew":[127,233],"mainly":[128],"because":[129],"lack":[131],"efficacy":[133],"(18%)":[134],"or":[135],"AEs":[136,227,256],"(5%).":[137],"exposure:":[140],"684":[141],"days":[142],"(range,":[143],"10\u20131793).":[144],"top":[146],"dose:":[148],"25":[149],"(IQR,":[151],"24\u201331).":[152],"Baseline":[153],"(IQR)":[155],"frequency:":[158],"28":[159],"(4\u201387)":[160],"for":[161,165,170,299,313,327,353,358,371,377,390,396],"FAS,":[162],"22":[163],"(7\u201376)":[164],"FIAS,":[166],"12":[168],"(4\u201341)":[169],"FBTCS.":[171],"reduction":[178,277],"67%\u201399%":[180],"61%\u201378%":[182],"50%\u201381%":[185],"The":[187,201,210],"FAS":[188],"RRs":[189,203,212],"61%\u201388%":[191],"(\u226550%":[192],"reduction),":[193,196],"45%\u201372%":[194],"(\u226575%":[195],"20%\u201346%":[198],"(100%":[199],"reduction).":[200],"FIAS":[202],"55%\u201369%,":[205],"41%\u201356%,":[206],"18%\u201329%,":[208],"respectively.":[209,218],"FBTCS":[211],"52%\u201369%,":[214],"41%\u201354%,":[215],"23%\u201336%,":[217],"Among":[219],"any":[222],"seizure,":[224],"90%":[225],"reported":[226],"38%":[229],"serious":[230],"AEs;":[231],"7%":[232],"due":[234],"AEs.":[236],"Five":[237],"deaths,":[238],"not":[239],"considered":[240],"treatment-related,":[241],"occurred":[242],"cohort.":[245],"AEs:":[248],"diarrhea":[249],"(40%),":[250],"convulsion":[251],"(24%),":[252],"somnolence":[253],"(21%).":[254],"Liver-related":[255],"(>1%)":[257],"increased":[259],"ALT":[260],"AST":[262],"(4%":[263],"each)":[264],"abnormal":[266],"liver":[267],"function":[268],"test":[269],"(3%).":[270],"Conclusions:":[271],"an":[282,302,316,330],"acceptable":[283],"safety":[284],"profile.":[285],"Disclosure:":[286],"Dr.":[287,293,307,321,335,342,360,379],"Park":[288],"has":[289,295,309,323,337,344,362,381],"nothing":[290],"disclose.":[292],"Rajasekaran":[294],"personal":[297,311,325,346,364,383],"compensation":[298,312,326,347,365,384],"serving":[300,314,328,354,372,391],"as":[301,315,329,355],"employee":[303,317,331],"Jazz":[305,319,333,340,397],"Pharmaceuticals.":[306,320,398],"Greco":[308],"Sahebkar-Moghaddam":[322,336],"pharmaceuticals.":[334,341],"stock":[338],"Flamini":[343,361,380],"range":[350,368,387],"$0-$499":[352],"Consultant":[357],"Biocodex.":[359],"$500-$4,999":[370,389],"on":[373,392],"Speakers":[375,394],"Bureau":[376,395],"Eisai.":[378]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2024-04-10T00:00:00"}